TScan Therapeutics Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, TScan Therapeutics stock has a consensus rating of "Buy" and an average price target of $6.00. The average 1-year stock price forecast is 552.17% higher than the current stock price, while the lowest is $5.00 (+443.48%) and the highest is $7.00 (+660.87%).

Price Target: $6.00 (+552.17%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$5.00	$6.00	$6.00	$7.00
Change	+443.48%	+552.17%	+552.17%	+660.87%

* Price targets were last updated on May 8, 2026.

Analyst Ratings

The average analyst rating for TScan Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Nov '25	Dec '25	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	4	4	4	4	4	4
Buy	1	1	1	1	1	1
Hold	2	2	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	7	7	6	6	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
David Nierengarten Wedbush	Wedbush	Buy Maintains $5	Buy	Maintains	$5	+443.48%	May 8, 2026
Sam Slutsky LifeSci Capital	LifeSci Capital	Buy Reiterates $6	Buy	Reiterates	$6	+552.17%	May 7, 2026
Gil Blum Needham	Needham	Buy Maintains $6	Buy	Maintains	$6	+552.17%	May 6, 2026
Andres Y. Maldonado H.C. Wainwright	H.C. Wainwright	Buy Reiterates $7	Buy	Reiterates	$7	+660.87%	May 6, 2026
Maxwell Skor Morgan Stanley	Morgan Stanley	Hold Maintains n/a	Hold	Maintains	n/a	n/a	Mar 12, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

7.56M

from 10.33M

-26.80%

from 10.33M

Revenue Next Year

7.81M

from 7.56M

3.30%

from 7.56M

EPS This Year

-0.84

from -1.00

EPS Next Year

-0.89

from -0.84

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	10.14M	13.54M	21.05M	2.82M	10.33M	7.56M
Revenue Growth	834.65%	33.47%	55.52%	-86.62%	266.66%	-26.80%
Gross Profit	-34.81M	-46.28M	-67.10M	-104.53M	-102.23M	7.56M
Gross Margin	-343.29%	-341.96%	-318.80%	-3,712.14%	-990.07%	100.00%
Operating Income	-48.64M	-66.64M	-93.46M	-134.82M	-133.81M	-119.99M
Net Income	-48.63M	-66.22M	-89.22M	-127.50M	-129.77M	-115.07M
EPS	-	-	-	-	-1.00	-0.84
Free Cash Flow	-33.43M	-42.84M	-41.83M	-68.97M	-97.25M	-77.47M
No. Analysts	-	-	-	-	-	5

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	10.8M
Avg	7.6M
Low	982,000

Revenue Growth

Revenue Growth	2026	2027	2028
High	5.0%
Avg	-26.8%
Low	-90.5%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.84
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-